Search

Your search keyword '"Heung Yong Jin"' showing total 3 results
Start Over Author "Heung Yong Jin" Publisher korean endocrine society
3 results on '"Heung Yong Jin"'

1. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

Author

Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, and Chong Hwa Kim

Subjects
Acromegaly, Somatostatin analogues, Octreotide, Lanreotide, Pasireotide, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Published
2019
Full Text
View/download PDF

2. Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

Author

Kyeong Hye Park, Se Hwa Kim, Jung Min Lee, Kyung Ae Lee, Min Jeong Kwon, Jung Soo Lim, Ha Young Kim, Dong Jun Lim, Kee Ho Song, Eun Jig Lee, Hyun Koo Yoon, Heung Yong Jin, Dong Yeob Shin, Jung Hee Kim, Dong Sun Kim, Jin Hwa Kim, Seong-Su Moon, Seungjoon Oh, Kwang Joon Kim, Chong Hwa Kim, Cheol Ryong Ku, Dae Jung Kim, Sang Ouk Chin, Sung Woon Kim, and Byung Joon Kim

Subjects
Position statement, medicine.medical_specialty, Consensus, Antineoplastic Agents, Hormonal, Endocrinology, Diabetes and Metabolism, Dose interval, Decision Making, Antineoplastic Agents, Somatostatin analogues, Octreotide, Lanreotide, Injections, Intramuscular, Peptides, Cyclic, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Special Article, chemistry.chemical_compound, Endocrinology, Republic of Korea, Acromegaly, Health insurance, Humans, Medicine, Expert Testimony, Insurance, Health, lcsh:RC648-665, Medical treatment, business.industry, Neuroendocrinology, medicine.disease, Pasireotide, Somatostatin, Attitude, chemistry, Family medicine, Practice Guidelines as Topic, Preoperative Period, business
Abstract

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Published
2019

3. A Case of Simultaneous Presentation of Thyroid Crisis and Diabetic Ketoacidosis

Author

Heung Yong Jin, Kyung Taek Park, Kyung Ae Lee, Ji Hyun Park, Hea Min Yu, Hong Sun Baek, and Tae Sun Park

Subjects
Endocrinology, Diabetic ketoacidosis, business.industry, Endocrinology, Diabetes and Metabolism, medicine, Thyroid Crisis, University medical, Medical emergency, Presentation (obstetrics), medicine.disease, business, University hospital
Abstract

Received: 14 April 2011, Accepted: 15 September 2011 Corresponding author: Tae Sun Park Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju 561-712, Korea Tel: +82-63-250-1794, Fax: +82-63-254-1609, E-mail: pts@chonbuk.ac.kr A Case of Simultaneous Presentation of Thyroid Crisis and Diabetic Ketoacidosis Kyung Ae Lee, Kyung Taek Park, Hea Min Yu, Heung Yong Jin, Ji Hyun Park, Hong Sun Baek, Tae Sun Park Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results